Rome Ellen, Ziegler Julie, Secic Michelle, Bonny Andrea, Stager Margaret, Lazebnik Rina, Cromer Barbara A
Children's Hospital at the Cleveland Clinic, Cleveland, Ohio, USA.
J Pediatr Adolesc Gynecol. 2004 Dec;17(6):373-7. doi: 10.1016/j.jpag.2004.09.013.
To examine the relationship between biochemical markers of bone metabolism and hormonal contraception in adolescents.
A prospective, observational design.
The study was conducted in four adolescent health clinics in a large metropolitan area.
The study population comprised healthy, postmenarcheal adolescent girls aged 12-18 initiating either medroxyprogesterone acetate (n=53) or an oral contraceptive (OC) containing 20 mug ethinyl estradiol/100 mug levonorgestrel (n=165) and those using no hormonal contraception (n=152).
None.
Serum bone specific alkaline phosphatase (BSAP), urinary deoxypyridinoline (DPD), and bone mineral density (BMD) at baseline and 12 months.
At 12 month follow-up, serum BSAP levels were significantly higher (P < 0.05) in the control group (40.4 U/L +/- 1.03 SE), than in the DMPA group (35.2 U/L +/- 1.05 SE) and the OC group (35.5 U/L +/- 1.03 SE). There was a trend in urinary DPD levels to be higher (P=0.08) in the control group (9.9 nmol/mmol Cr +/- 1.03 SE) than in the DMPA group (9.1 +/- 1.05 SE) and the OC group (8.9 +/- 1.03 SE). No relationship was found between the biochemical markers and BMD at the lumbar spine or the femoral neck.
Over 12 months, there was evidence of increased bone formation and resorption in the control group when compared to that in the DMPA and OC groups. This finding may indicate a suppression of bone metabolism in girls using DMPA or an OC containing 20 mug ethinyl estradiol/100 mug levonorgestrel.
探讨青少年骨代谢生化标志物与激素避孕之间的关系。
前瞻性观察性设计。
研究在一个大城市地区的四家青少年健康诊所进行。
研究人群包括健康的初潮后12至18岁青少年女孩,其中开始使用醋酸甲羟孕酮的有53人,使用含20μg炔雌醇/100μg左炔诺孕酮口服避孕药(OC)的有165人,以及未使用激素避孕的有152人。
无。
基线及12个月时的血清骨特异性碱性磷酸酶(BSAP)、尿脱氧吡啶啉(DPD)和骨密度(BMD)。
在12个月的随访中,对照组(40.4 U/L±1.03标准误)的血清BSAP水平显著高于醋酸甲羟孕酮组(35.2 U/L±1.05标准误)和口服避孕药组(35.5 U/L±1.03标准误)(P<0.05)。对照组(9.9 nmol/mmol肌酐±1.03标准误)的尿DPD水平有高于醋酸甲羟孕酮组(9.1±1.05标准误)和口服避孕药组(8.9±1.03标准误)的趋势(P = 0.08)。未发现生化标志物与腰椎或股骨颈骨密度之间存在关联。
与醋酸甲羟孕酮组和口服避孕药组相比,对照组在12个月期间有骨形成和骨吸收增加的证据。这一发现可能表明使用醋酸甲羟孕酮或含20μg炔雌醇/100μg左炔诺孕酮口服避孕药的女孩骨代谢受到抑制。